The Lancet: Experimental drug for spinal muscular atrophy shows promising early results, prompting phase 3 clinical trial

December 06, 2016

A new drug for spinal muscular atrophy has shown promising early results in a phase 2 trial involving 20 babies with infantile-onset spinal muscular atrophy. The study, published in The Lancet, found that nusinersen was safe and improved muscle function and nerve activity in most babies. While the drug does not represent a cure, the findings are an important first step and have prompted a larger phase 3 clinical trial.

Spinal muscular atrophy is a genetic disease that affects around one in every 11000 births. It affects the nerve cells in the spinal cord that connect to the muscles, causing them to waste away resulting in progressive muscle weakness and difficulties breathing and eating.

Infantile-onset is the most severe form of the disease, affecting 60% of those diagnosed with spinal muscular atrophy. It affects babies under six months old and less than a quarter of those diagnosed will live to two years old without major feeding and breathing support. Until now there has been no effective treatment for the disease other than providing permanent supportive care.

In the study of 20 babies aged one to seven months, researchers tested the safety, effectiveness and mechanism of action of the nusinersen drug, which is designed to modify the way the body reads the SMN2 gene to increase the production of SMN protein in these infants and children with spinal muscular atrophy. The trial did not include a control group and was 'open-label', meaning that doctors and parents knew the babies were being given the drug.

"While our results are promising this drug does not represent a cure. We observed remarkable improvement in muscle function, for instance some babies undergoing treatment developed the ability to sit and roll over independently, and improved their head control, kicking, grasping, standing and even walking. Although this type of improvement has not been observed before in infants with infantile-onset spinal muscular atrophy, the drug did not restore normal levels of muscle function." said lead author Dr Richard Finkel from Nemours Children's Hospital, USA. "It's important to interpret these findings carefully as our study is relatively small and open-label, but this is an important first step."

The first four patients were given a low dose (6mg) of nusinersen for their first three doses to confirm that it was safe before being given the higher dose (12mg) at each four month treatment visit. The next 16 patients were given the higher dose throughout the trial. The drug was injected directly into the spinal fluid via a lumbar puncture.

Four babies died of their disease during the study including one who died too early to be included in the analysis. All participants experienced adverse events linked to their disease, with 16 babies experiencing 77 serious adverse events such as difficulties breathing or respiratory infections which were considered by the investigators not to be drug-related. One baby developed mild neutropenia (low white blood cell count) and another had mild vomiting possibly linked to the drug.

During the trial the babies' muscle function was assessed using two tests that measured their ability to perform certain tasks (head control, sitting, grasping, kicking, rolling, crawling, standing and walking) and their overall muscle function.

Muscle skills improved in 16 out of 20 babies and the biggest improvements were in their ability to grasp, kick and sit (for 13, nine and eight babies, respectively - see figure 1B). Overall muscle function improved in 14 of 18 babies, for whom measurements were available, with the average muscle function score increasing by 11.5 points (on the 64-point CHOP-INTEND motor function scale) during their treatment time. When babies are not treated this score typically declines by 1.27 points each year, as shown in a comparison study.

The researchers also found that responses generated from the peroneal nerve (located behind the knee) increased for babies given high dose nusinersen, and responses from the ulnar nerve (located at the wrist) increased in 12 of the 15 babies for whom nerve activity measurements were available.

The researchers were unable to calculate an average survival for those on the drug as most babies were still alive - with 16 babies surviving without requirement for permanent breathing support during the trial's treatment period, which ranged from 18 to 32 months.

The study demonstrated that nusinersen, when administed by lumbar puncture (spinal tap), was effectively absorbed from the spinal fluid into the spinal cord and brain tissue and targeted the nerve cells that are most affected in spinal muscular atrophy. This was performed by testing tissue samples from three babies who died during the study, providing proof of the drug's action.

The researchers note that the small number of patients in the trial, the short follow-up period and that it was an open-label study limit the findings of the study. Typically, phase 3 trial results are needed to confirm results from phase 2 clinical trials.

Writing in a linked Comment, Professor Thomas Gillingwater, University of Edinburgh, UK, said "The new open-label, phase 2 clinical study ... represents a major milestone on the journey towards a viable therapy... Whilst these findings need to be interpreted cautiously in the context of the obvious limitations of a small, open-label interventional trial, they should generate significant encouragement that elevating SMN protein levels is likely to be of therapeutic benefit to spinal muscular atrophy patients."

The study was funded by Ionis Pharmaceuticals Inc and Biogen. It was conducted by researchers from Nemours Children's Hospital, Columbia University Medical Center, University of Toronto, Stanford University and Ionis Pharmaceuticals. A declaration of interests is available in the Article.

[1] Quote direct from author and cannot be found in the text of the Article.


The Lancet

Related Spinal Cord Articles from Brightsurf:

Stem cells can help repair spinal cord after injury
Spinal cord injury often leads to permanent functional impairment. In a new study published in the journal Science researchers at Karolinska Institutet in Sweden show that it is possible to stimulate stem cells in the mouse spinal cord to form large amounts of new oligodendrocytes, cells that are essential to the ability of neurons to transmit signals, and thus to help repair the spinal cord after injury.

Improving treatment of spinal cord injuries
A group led by UC Riverside bioengineering professor Victor G.

Spinal cord gives bio-bots walking rhythm
Miniature biological robots are making greater strides than ever, thanks to the spinal cord directing their steps.

Co-delivery of IL-10 and NT-3 to enhance spinal cord injury repair
Spinal cord injury (SCI) creates a complex microenvironment that is not conducive to repair; growth factors are in short supply, whereas factors that inhibit regeneration are plentiful.

Locomotor engine in the spinal cord revealed
Researchers at Karolinska Institutet in Sweden have revealed a new principle of organization which explains how locomotion is coordinated in vertebrates akin to an engine with three gears.

Neurological signals from the spinal cord surprise scientists
With a study of the network between nerve and muscle cells in turtles, researchers from the University of Copenhagen have gained new insight into the way in which movements are generated and maintained.

An 'EpiPen' for spinal cord injuries
An injection of nanoparticles can prevent the body's immune system from overreacting to trauma, potentially preventing some spinal cord injuries from resulting in paralysis.

From spinal cord injury to recovery
Spinal cord injury disconnects communication between the brain and the spinal cord, disrupting control over part of the body.

Transplanting adult spinal cord tissues: A new strategy of repair spinal cord injury
Spinal cord injury repair is one of the most challenging medical problems, and no effective therapeutic methods has been developed.

Gene medication to help treat spinal cord injuries
The two-gene medication has been proven to recover motor functions in rats.

Read More: Spinal Cord News and Spinal Cord Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to